The Tumor Treating Fields Mesothelioma Case Study You'll Never Forget > 자유게시판

Tumor Treating Fields Mesothelioma

Tumor treating fields mesothelioma, a new type of treatment, uses alternating electric field to slow the growth of cancer. It is used in conjunction with chemotherapy to treat pleural mesothelioma.

After the successful STELLAR study The FDA approved TTFields together with pemetrexed cisplatin and in the year 2019. FDA approved TTFields. Patients may ask their doctor for this best treatment for mesothelioma.

Disrupting Cell Division

TTFields employ different electrical fields to disrupt cancer cell proteins and prevent the cells from dividing. This can stop mesothelioma from spreading or growing in other organs. TTFields work to stimulate the release of proteins that kill cancer cells and aid the immune system in fighting mesothelioma tumours.

During treatment patients wear a small device with insulated pads that stick to the skin. The device delivers a low-intensity electrical current, and the patient can control how much treatment they receive. The mesothelioma treatment session is typically 30 minutes. Patients can undergo the TTFields Treatment several times per day.

A TTFields 2021 study found that electrical fields ranging from 100 to 300 Kilohertz could stop cancer cell division and cause them to die. The study covered a variety of types of cancer cells and found that the electrical fields killed them all, regardless of their cellular shape.

The study's author suggested combining TTFields and chemotherapy for mesothelioma. Novocure's TTFields product, called NovoTTF 100L, was approved by the FDA in 2019 to treat pleural mesothelioma that is not resectable. It is now available from mesothelioma specialists in certified medical centers in the U.S. including the West Cancer Center, Memphis. The NovoTTF 100L device, also known as Optune Lua has been used to treat mesothelioma in combination with platinum-based chemotherapy and pemetrexed. Mesothelioma patients have reported an prolonged survival rate when the TTFields treatment is combined with chemotherapy.

Another study published in the journal "Lung Cancer" reported that TTFields therapy is effective in conjunction with chemotherapy. In the study researchers found that combining chemotherapy and TTFields reduced the number of malignant mesothelioma cells in animal models by more than 80 percent. The study also demonstrated that the combination of these two treatments increased the production of proteins that kill mesothelioma cancer cells and reduce the amount of cancerous DNA that is found in the body.

The TTFields procedure is a relatively recent treatment of malignant mesothelioma, and a lot of mesothelioma physicians do not provide it for patients suffering from pleural mesothelioma. Patients can still have access to this treatment for stage 1 mesothelioma through clinical trials or at mesothelioma clinics certified by Novocure.

Stalling Tumor Development

When mesothelial cancer cells multiply and exceed their normal lifespan they transform and cause an overabundance that grows and spreads throughout the body. The tumor treatment fields stop mesothelial cells from duplication which prevents mesothelioma from expanding and growing.

The TTFields device, which is worn on the chest as a vest, produces a series of electrical field that can alter protein, kill cancer cells, and slow down tumor development. The device comes with insulated pads that adhere to the skin. Patients or health care professionals can apply the pads at home.

Doctors recommend combining TTFields with chemotherapy for the most effective results. The combination boosts the production of proteins that kill cancer cells and reduces cancer cells' ability to repair DNA damage caused by chemotherapy drugs. This makes chemotherapy drugs to work harder and increase survival rates in mesothelioma.

In the STELLAR trial conducted in 2017, TTFields therapy in combination with chemotherapy significantly increased survival for mesothelioma patients. The FDA approved the NovoTTF-100L system and is now marketed as Optune Lua, for use in conjunction with pemetrexed and carboplatin or cisplatin as the first-line treatment for malignant mesothelioma treatment unresectable mesothelioma pleural in the year 2019.

Researchers have found that the TTFields treatment can fight mesothelioma by stopping cell division. The treatment TTFields induces cancer cells to break down through a process known as mitosis, and then the cellular debris gets trapped in surrounding tissues, which inhibits the development of new tissues. Mitosis also prevents mesothelioma cells from repair damaged DNA and makes cells more prone to radiation treatment.

The TTFields therapy also helps to reduce the flow of blood from tumors by suppression of vascular endothelial growth factor (VEGF) and the growth of hypoxia-inducible factors-1 alpha or HIF-1a. HIF-1a is linked to cancer cells' angiogenesis.

If you are diagnosed with mesothelioma or other cancers, talk with your doctor about whether TTFields is a good option for you. Novocure and mesothelioma experts are working together on clinical trials to evaluate the efficacy of TTFields. To find out more about how mesothelioma TTFields could help your treatment plan get in touch with a Novocure certified specialist at one of more than 1,300 U.S. treatment centers.

Killing Tumor Cells

Tumor-treating fields (TTFields) which transmit electrical waves throughout the body, disrupt cell division and eliminate cancerous cells. TTFields target cancerous cells, while protecting healthy cells. These electric fields also reduce DNA repair and increase cell defenses, making it harder for cancerous cells to survive. TTF is non-invasive and causes very few side effects besides minor skin irritation.

Scientists believe TTFields function by disrupting mitosis, the process where the cell divides into two identical new cells. Normal cells have controls in place to limit the rate of mitosis however cancerous malignancies break this control and multiply in a rapid rate. TTFields interferes with this process by blocking signals that control the process of mitosis in mesothelioma cancer cells. In the STELLAR study, TTFields combined with chemotherapy significantly improved survival rates in mesothelioma patients. Mesothelioma patients who received TTFields in addition to maintenance cycles of chemotherapy were able to live on average six months longer than patients who received chemotherapy alone.

In a separate study, it was found that TTFields could increase the effectiveness of certain chemotherapy drugs known as platinum-based treatments. These platinum-based treatments destroy mesothelioma cells through targeting the mitochondria, which is where cancerous cells get their energy from. When TTFields are utilized in conjunction with these chemotherapy drugs, the combination could result in greater DNA damage, and faster death of cancer cells.

In certain instances, TTFields also increase the effects of radiation therapy. Scientists have observed that mixing TTFields with radiation therapy could create a "synergistic effect." This means that the combined treatments increase the sensitivity of mesothelioma cells to radiation.

TTFields is currently only available in specific mesothelioma clinics. However, a mesothelioma expert can determine whether you may be qualified for this treatment. If you do qualify an attorney for mesothelioma can assist you in gaining access to treatment that can include TTFields in conjunction with chemotherapy. A mesothelioma lawyer can help veterans access VA-covered treatments.

Side Effects

The TT fields therapy disrupts cancer cells by creating an electrical field that blocks the cell's ability to divide. This could slow down the growth of tumors and prevent them from spreading to other areas of the body. The TT fields device is noninvasive, which means it doesn't harm the tissues around it or cause pain. This is a different treatment than conventional chemotherapy, which involves radiation and intravenous injections, tumor treating fields mesothelioma which can cause serious side effects.

In an experiment, patients who received a combination of TT fields and temozolomide saw survival improvements comparable to people who were only treated with chemotherapy. Doctors attributed the improved survival to the TT fields their ability to enhance the effectiveness of chemo and reduce side effects.

Mesothelioma cancer cells can transform into cancerous cells, and then reproduce uncontrollably, forming an aggressive tumor that takes over the organs of your body. By halting cell division, mesothelioma treatment such as TT fields prevent mesothelioma cancer cells from reproducing and hindering the body's normal functions.

In a mesothelioma-related study patients who received TT fields together with chemotherapy had an average survival rate of 18.2 months. Patients who received TT fields but not chemotherapy had a survival rate of 12.1.

The pleura, or thin lining of your lungs can be treated by applying the treatment fields to the abdominal wall or chest. The device is small enough to wear for up to 18 hours a day, even during sleep. This allows patients to live their lives and work while undergoing treatment.

TT fields can be added with conventional chemotherapy or immunotherapy as well as other mesothelioma treatment. Patients with mesothelioma who are interested in TT fields should discuss this possibility with their mesothelioma doctor, who can explain the eligibility requirements and anticipated benefits for the patient's particular situation.